Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement
Christine E. Ryan(Dana-Farber Cancer Institute), Reid W. Merryman(Harvard University), Robert Redd(Harvard University), Lakshmi Nayak(Dana-Farber Cancer Institute), Roni Shouval(Memorial Sloan Kettering Cancer Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Hossein Sadrzadeh(Massachusetts General Hospital), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Philippe Armand(Harvard University), Ugonma Chukwueke, Zachary D. Epstein‐Peterson(Memorial Sloan Kettering Cancer Center), Matthew J. Frigault(Harvard University), Jennifer L. Crombie(Dana-Farber Cancer Institute), Anita Kumar(Memorial Sloan Kettering Cancer Center), Austin I. Kim(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Rebecca L. Zon(Brigham and Women's Hospital)
Cited by 16
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560